Literature DB >> 9260150

Compliance/adherence and care management in HIV disease.

M Crespo-Fierro1.   

Abstract

With the changing perspectives of the HIV epidemic and the introduction of protease inhibitors to treat human immunodeficiency virus (HIV) disease, the issue of compliance has gained considerable interest among health care providers. The idea that clients with HIV disease should succumb to a patriarchal system of medical care has been challenged by AIDS activists since the beginning of the epidemic. The concept that there is only one explanation for "noncompliance" is outdated. The reasons for noncompliance are multifaceted in nature and include psychosocial factors, complex medication and treatment regimens, ethnocultural concerns, and in many instances substance use. Therefore, the notion that there is one intervention to resolve noncompliance is at best archaic. Interventions to enhance compliance include supervised therapy, improving the nurse-client relationship, and patient education, all of which should be combined with ethnocultural interventions. Plans to enhance compliance must incorporate person-specific variables and should be tailored to individualized needs.

Entities:  

Mesh:

Year:  1997        PMID: 9260150     DOI: 10.1016/S1055-3290(97)80012-X

Source DB:  PubMed          Journal:  J Assoc Nurses AIDS Care        ISSN: 1055-3290            Impact factor:   1.354


  7 in total

1.  Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study.

Authors:  Otilia Elisabeta Benea; Adrian Streinu-Cercel; Carmen Dorobăţ; Sorin Rugină; Lucian Negruţiu; Augustin Cupşa; Dan Duiculescu; Carmen Chiriac; Corina Itu; Liviu Jany Prisăcariu; Ionel Iosif
Journal:  Germs       Date:  2014-09-01

2.  To tell or not to tell: why people with HIV share or don't share with their physicians whether they are taking their medications as prescribed.

Authors:  H Kremer; G Ironson
Journal:  AIDS Care       Date:  2006-07

3.  Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group.

Authors:  M P Carrieri; J P Moatti; D Vlahov; Y Obadia; C Reynaud-Maurupt; M Chesney
Journal:  J Epidemiol Community Health       Date:  1999-01       Impact factor: 3.710

4.  Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals.

Authors:  Gita Suneja; Meredith S Shiels; Sharon K Melville; Melanie A Williams; Ramesh Rengan; Eric A Engels
Journal:  AIDS       Date:  2013-01-28       Impact factor: 4.177

Review 5.  Tailored treatment for HIV+ persons with mental illness: the intervention cascade.

Authors:  Michael B Blank; Marlene M Eisenberg
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

6.  Adherence to antibiotic prophylaxis in children with vesicoureteral reflux.

Authors:  Esequiel Rodriguez; Dana A Weiss; Hillary L Copp
Journal:  Adv Urol       Date:  2011-03-27

7.  A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study.

Authors:  Mike Youle; Sean Emery; Martin Fisher; Mark Nelson; Lisa Fosdick; George Janossy; Clive Loveday; Ann Sullivan; Christian Herzmann; Handan Wand; Richard T Davey; Margaret A Johnson; Jorge A Tavel; H Clifford Lane
Journal:  PLoS Clin Trials       Date:  2006-05-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.